Actym Therapeutics and Wacker Biotech Sign Manufacturing Contract for Actym’s Lead Candidate for the Treatment of Solid Tumors

BERKELEY, Calif. and AMSTERDAM, Feb. 28, 2022 /PRNewswire/ -- Actym Therapeutics, a biotechnology company focused on the discovery and development of novel therapies intended to transform the treatment of cancer, and Wacker Biotech announced today that they have signed a contract for the...

Click to view original post